HEPATITIS C: THE STATE OF MEDICAID ACCESS

The Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) share a commitment to ensuring that all individuals living with hepatitis C (HCV) are able to access the cure for HCV, the deadliest infectious disease in the United States. We are pleased to report that our collective advocacy since 2014 is working.

In particular, the launch of our Hepatitis C: The State of Medicaid Access report in 2017 has successfully supported efforts to eliminate treatment access restrictions. Since 2017, 30 states have either eliminated or reduced their fibrosis restrictions, 17 have loosened their sobriety restrictions, and 20 have scaled back their prescriber restrictions.

While we have enjoyed numerous successes over the past year, our work is ongoing as states persist in imposing discriminatory treatment access restrictions. CHLPI and NVHR remain committed to capitalizing on the momentum we enjoy today and to advocating for the removal of all states' HCV treatment access restrictions.

Eliminating treatment access restrictions is a necessary step toward ending HCV in the United States. We have the tools to eliminate HCV, but it requires the removal of all discriminatory HCV treatment access restrictions as well as leadership and resources to turn the promise of the cure into a reality for all.

For more information about Hepatitis C: The State of Medicaid Access please go to www.stateofhepc.org.


Updated August 01, 2020







FIBROSIS RESTRICTIONS 2014 2020







FIBROSIS RESTRICTIONS AS OF 8/01/2020

S 0 Florida Ţ U Idaho lowa + 5 0 R Maine 0 Ζ

Alaska Nevada Arizona California Colorado Connecticut Delaware District of Columbia North Dakota Georgia Hawaii Illinois Indiana Kansas Kentucky Louisiana Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana

New Hampshire **New Jersey New Mexico** New York **North Carolina** Ohio Oklahoma Oregon **Pennsylvania** Puerto Rico **Rhode Island** South Carolina Tennessee Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

Alabama Nebraska

Arkansas South Dakota Texas

Percentage 90% of States

Number of 147 **States**




Percentage 4% of States

Number of 2 **States**



Bolded text indicates movement since October 2017

SOBRIETY RESTRICTIONS20142020








SOBRIETY RESTRICTIONS AS OF 8/01/2020



Bolded text indicates movement since October 2017

PRESCRIBER RESTRICTIONS 2014 2020







PRESCRIBER RESTRICTIONS AS OF 8/01/2020

o Restrictions

Ζ

North Carolina Alabama Oregon Alaska Pennsylvania California **Rhode Island** Connecticut Tennessee Delaware Virginia Florida Washington Georgia Wisconsin Wyoming Idaho Kansas Kentucky Louisiana Maine Maryland Massachusetts Minnesota Missouri Montana Nebraska New Mexico **New York**

	Arizona
2	Colorado
	District of Columbia
	Hawaii
D	Illinois
	lowa
5	Indiana
n	Michigan
	Mississippi
	Nevada
	New Hampshire
	North Dakota
	Ohio
	Oklahoma
	South Carolina
	South Dakota
)	Texas
	Utah
	Vermont
	West Virginia

. .

Arkansas New Jersey Puerto Rico

J

Percentage of States | 56%

Number of States

29

Percentage of States 38% Number of States 20

Percentage of States 6% Number of States 3